NCT00327379 - Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2006

Primary Completion Date

March 1, 2007

Study Completion Date

March 1, 2007

Conditions

Blood Loss, SurgicalPostoperative Hemorrhage

Interventions

DRUG

Trasylol (Aprotinin, BAYA0128)

Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)

DRUG

Placebo

Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)

Trial Locations (14)

Berlin

Berlin

Neustadt

Madrid

Pamplona

Valencia

Münster

Karlsbad

Oshawa

Windsor

Montreal

Barcelona

Barcelona

Barcelona